ES2183869T3 - Emulsiones de aceite en agua que contienen propofol y edetato. - Google Patents

Emulsiones de aceite en agua que contienen propofol y edetato.

Info

Publication number
ES2183869T3
ES2183869T3 ES95911412T ES95911412T ES2183869T3 ES 2183869 T3 ES2183869 T3 ES 2183869T3 ES 95911412 T ES95911412 T ES 95911412T ES 95911412 T ES95911412 T ES 95911412T ES 2183869 T3 ES2183869 T3 ES 2183869T3
Authority
ES
Spain
Prior art keywords
edetate
oil emulsions
emulsions containing
water oil
containing propofol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95911412T
Other languages
English (en)
Inventor
Christopher Buchan Jones
John Henry Platt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48793621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2183869(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2183869T3 publication Critical patent/ES2183869T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES FARMACEUTICAS QUE CONTIENEN 2,6 DIISOPROPILFENOL (PROPOFOL) PARA SU UTILIZACION COMO ANESTESICOS. SE DESCRIBE UN PROCEDIMIENTO PARA SU PREPARACION, ASI COMO SU UTILIZACION PARA PRODUCIR ANESTESIA, INCLUYENDO LA INDUCCION Y EL MANTENIMIENTO DE LA ANESTESIA GENERAL Y LA SEDACION.
ES95911412T 1994-03-22 1995-03-17 Emulsiones de aceite en agua que contienen propofol y edetato. Expired - Lifetime ES2183869T3 (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GB9405593A GB9405593D0 (en) 1994-03-22 1994-03-22 Pharmaceutical compositions
CA002212794A CA2212794C (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
CH01282/04A CH694423A5 (de) 1994-03-22 1995-03-17 Verwendung von Edetat zur Stabilisierung von pharmzeutischen Zusammensetzungen.
CH00393/03A CH693762A5 (de) 1994-03-22 1995-03-17 Wässrige Zusammensetzungen enthaltend eine Öl-in-Wasser-Emulsion
BE9500241A BE1009198A5 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol.
DE19509828A DE19509828A1 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzungen
HU9702180A HU227951B1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and disodium edetate
ZA952239A ZA952239B (en) 1994-03-22 1995-03-17 Pharmaceutical compositions
NZ500588A NZ500588A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate for producing anaesthesia
NZ282005A NZ282005A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol (2,6 diisopropylphenol) and edetate
PL95322278A PL186354B1 (pl) 1994-03-22 1995-03-17 Jałowe kompozycje farmaceutyczne oraz sposoby ograniczania potencjału wzrostowego drobnoustrojów i poprawiania czasu stosowania emulsji
PCT/GB1995/000579 WO1996029064A1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
FR9503128A FR2731617B1 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol
BR9510452A BR9510452A (pt) 1994-03-22 1995-03-17 Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos
EP95911412A EP0814787B1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and disodium edetate
CH02011/97A CH693764A5 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat.
NO19974278A NO320007B1 (no) 1994-03-22 1997-09-16 Steril farmasoytisk blanding inneholdende propofol og edetat for parenteral administrering, fremgangsmate for a begrense potensialet for mikrobevekst i blandingen, samt anvendelse derav.
JP00624199A JP4012328B2 (ja) 1994-03-22 1999-01-13 エデテートを含有する水中油滴エマルジョン
FI20085586A FI120641B (fi) 1994-03-22 2008-06-13 Ruuansulatuskanavan ulkopuolisesti annettavat rasvaemulsiot, jotka sisältävät edetaattia säilöntäaineena

Publications (1)

Publication Number Publication Date
ES2183869T3 true ES2183869T3 (es) 2003-04-01

Family

ID=48793621

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02009330T Expired - Lifetime ES2253469T3 (es) 1994-03-22 1995-03-17 Emulsiones grasas parenterales que comprenden edetato como conservante.
ES95911412T Expired - Lifetime ES2183869T3 (es) 1994-03-22 1995-03-17 Emulsiones de aceite en agua que contienen propofol y edetato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES02009330T Expired - Lifetime ES2253469T3 (es) 1994-03-22 1995-03-17 Emulsiones grasas parenterales que comprenden edetato como conservante.

Country Status (32)

Country Link
US (1) US5714520A (es)
EP (2) EP1238677B1 (es)
JP (2) JP3067806B2 (es)
AT (2) ATE226817T1 (es)
AU (1) AU710143B2 (es)
BE (1) BE1009198A5 (es)
BR (1) BR9510452A (es)
CA (1) CA2212794C (es)
CH (4) CH693764A5 (es)
CZ (1) CZ297549B6 (es)
DE (2) DE19509828A1 (es)
DK (3) DK0814787T3 (es)
ES (2) ES2253469T3 (es)
FI (2) FI120640B (es)
FR (1) FR2731617B1 (es)
GB (2) GB9405593D0 (es)
HU (1) HU227951B1 (es)
IL (1) IL113021A (es)
IT (1) IT1281193B1 (es)
LU (1) LU90136B1 (es)
MX (1) MX9707005A (es)
NO (2) NO320007B1 (es)
NZ (2) NZ282005A (es)
PL (1) PL186354B1 (es)
PT (1) PT814787E (es)
RU (1) RU2147432C1 (es)
SE (2) SE523909C2 (es)
SI (1) SI0814787T1 (es)
SK (1) SK286375B6 (es)
TW (1) TW458781B (es)
WO (1) WO1996029064A1 (es)
ZA (1) ZA952239B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
KR19980025601A (ko) * 1996-10-04 1998-07-15 우동일 혈관주사제용 프로포폴 유탁액의 제조방법
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
CO4810371A1 (es) 1998-02-10 1999-06-30 Gensia Sicor Inc Composicion de propofol que contiene sulfito
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
JP4198318B2 (ja) * 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
CN1151782C (zh) * 1999-01-28 2004-06-02 迪内希·尚蒂拉尔·帕特尔 一种具有哺乳动物麻醉的诱导和保持以及镇静用途的药用注射液
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
JP2003502363A (ja) * 1999-06-21 2003-01-21 コンイル ファーマシューティカル カンパニー、リミテッド プロポフォールを含有する静脈内注射用麻酔剤組成物
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
AU2001258592A1 (en) * 2000-05-25 2001-12-03 Astrazeneca Ab Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
AU6689601A (en) 2000-06-16 2002-01-02 Rtp Pharma Inc Improved injectable dispersions of propofol
IN188917B (es) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
CN1525856A (zh) 2001-05-11 2004-09-01 三菱制药株式会社 含吡唑啉酮衍生物的稳定的高浓度注射剂
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US8541472B2 (en) 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
KR20040080444A (ko) * 2001-12-28 2004-09-18 길포드 파마슈티컬스 인코포레이티드 수용성인 프로포폴 전구약물의 약학적 수성 제제
DK1509492T3 (da) 2002-01-25 2011-11-28 Theravance Inc Sedative hypnotiske midler med kort virkningsvarighed til anæstesi og sedation
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20050203068A1 (en) * 2002-04-08 2005-09-15 Peggy Wingard Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CA2494297C (en) 2002-07-29 2011-10-18 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20040171691A1 (en) * 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
DK1648413T3 (da) * 2003-07-23 2010-01-11 Theravance Inc Farmaceutiske præparater af kortvirkende sedativt sövndyssende middel
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
WO2005044201A2 (en) * 2003-10-24 2005-05-19 Auspex Pharmaceuticals, Inc. Ph sensitive prodrugs of 2,6-diisopropylphenol
CA2556185C (en) 2004-02-13 2010-09-21 Bioavailability, Inc. A microemulsion preparation of high concentration propofol for anesthetic uses
WO2006030450A2 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2007000662A2 (en) * 2005-02-03 2007-01-04 Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
CN101184481A (zh) 2005-02-18 2008-05-21 阿布拉西斯生物科学公司 用于局部缺血性损伤的2,6-二异丙基苯酚和类似物的组合物，其使用和制备方法
US20090131538A1 (en) * 2005-05-27 2009-05-21 Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
RU2290169C1 (ru) * 2005-06-23 2006-12-27 Открытое Акционерное Общество "Фаберлик" Косметическое и/или дерматологическое средство и антиоксидант
EP1922060B1 (en) * 2005-08-05 2009-01-14 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
US20090203794A1 (en) * 2005-08-12 2009-08-13 Gautam Vinod Daftary Aqueous Anaesthetic Composition Comprising Propofol
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN1903187B (zh) * 2006-03-21 2012-05-30 沈阳药科大学 含有局麻药的复方异丙酚注射剂及制备工艺
EP2810927A1 (en) 2007-05-09 2014-12-10 Sowood Healthcare LLC Therapeutic compounds
CA2685813A1 (en) * 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
KR20080102010A (ko) * 2007-05-17 2008-11-24 대원제약주식회사 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
MX2011001240A (es) 2008-08-01 2011-08-12 Medicines Co Composiciones farmaceuticas y metodos para producir concentraciones de baja impureza de las mismas.
US9132090B2 (en) 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
CN102579555A (zh) * 2012-03-01 2012-07-18 四川大学华西医院 注射用脂肪乳在作为拮抗全身麻醉用药作用的药物制备中的应用
IN2014DN10322A (es) 2012-05-16 2015-08-07 Mewa Singh
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
US11357743B2 (en) 2017-04-19 2022-06-14 Mayo Foundation For Medical Education And Research Ketamine and propofol admixture

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3384545A (en) * 1965-03-09 1968-05-21 Hoffmann La Roche Injectable aqueous emulsions of fat soluble vitamins
US3230143A (en) * 1965-05-14 1966-01-18 Merck & Co Inc Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
DE1792410B2 (de) * 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Arzneimittelzubereitung zur intravenösen Injektion
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS5916818A (ja) * 1982-07-20 1984-01-28 Shimizu Seiyaku Kk 経静脈投与用輸液剤
SE8505047L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Fettemulsion
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4868169A (en) * 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steroid cream formulation
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
WO1990006055A1 (en) * 1988-11-29 1990-06-14 Unilever Plc Antimicrobial agents and uses thereof
GB8828517D0 (en) * 1988-12-07 1989-01-11 Leopold & Co Ag Stable emulsions
US5079003A (en) * 1990-03-14 1992-01-07 Adelia Scaffidi Skin lotions and creams
JP3308555B2 (ja) * 1991-03-08 2002-07-29 カネボウ株式会社 微細化エマルション組成物の製造方法
US5322689A (en) * 1992-03-10 1994-06-21 The Procter & Gamble Company Topical aromatic releasing compositions
JP2811036B2 (ja) * 1992-05-26 1998-10-15 参天製薬株式会社 ビタミンｅ点眼剤
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE69614855T2 (de) * 1995-06-06 2002-03-28 Biomolecular Products, Inc. Gemischte lipid-bicarbonat kolloidale partikel zur abgabe von arzneistoffen oder kalorien

Also Published As

Publication number Publication date
SE523909C2 (sv) 2004-06-01
DE69528714D1 (de) 2002-12-05
PL186354B1 (pl) 2003-12-31
GB2298789A (en) 1996-09-18
DE19509828A1 (de) 1996-09-19
DK106697A (da) 1997-09-17
FI120640B (fi) 2010-01-15
NZ282005A (en) 2000-01-28
SE9703274D0 (sv) 1997-09-10
SE0400115L (sv) 2004-01-21
JPH11263725A (ja) 1999-09-28
SE0400115D0 (sv) 2004-01-21
GB9505405D0 (en) 1995-05-03
IT1281193B1 (it) 1998-02-17
ATE312625T1 (de) 2005-12-15
EP1238677A3 (en) 2003-01-22
JPH11500737A (ja) 1999-01-19
CA2212794C (en) 2000-09-12
FI120641B (fi) 2010-01-15
DE69528714T2 (de) 2003-06-12
SK286375B6 (sk) 2008-08-05
FR2731617B1 (fr) 1997-05-30
JP4012328B2 (ja) 2007-11-21
ZA952239B (en) 1996-09-17
ES2253469T3 (es) 2006-06-01
IL113021A (en) 2001-04-30
IL113021A0 (en) 1995-12-08
SI0814787T1 (en) 2003-04-30
CH694423A5 (de) 2005-01-14
CH693762A5 (de) 2004-01-30
CH693764A5 (de) 2004-01-30
NO20041838L (no) 1997-09-16
GB2298789B (en) 1999-12-08
BE1009198A5 (fr) 1996-12-03
LU90136B1 (de) 1997-11-27
NO974278D0 (no) 1997-09-16
TW458781B (en) 2001-10-11
JP3067806B2 (ja) 2000-07-24
SE9703274L (sv) 1997-09-10
PT814787E (pt) 2003-02-28
NO974278L (no) 1997-09-16
PL322278A1 (en) 1998-01-19
NO320007B1 (no) 2005-10-10
FI20085586L (fi) 2008-06-13
NZ500588A (en) 2001-04-27
ITMI950529A1 (it) 1996-09-17
CZ297549B6 (cs) 2007-02-07
ATE226817T1 (de) 2002-11-15
RU2147432C1 (ru) 2000-04-20
EP1238677A2 (en) 2002-09-11
HU227951B1 (en) 2012-07-30
US5714520A (en) 1998-02-03
AU1898895A (en) 1996-10-08
FI973702A0 (fi) 1997-09-16
GB9405593D0 (en) 1994-05-11
HUT77358A (hu) 1998-03-30
CZ290497A3 (en) 1997-12-17
FR2731617A1 (fr) 1996-09-20
WO1996029064A1 (en) 1996-09-26
NO334956B1 (no) 2014-08-04
SK124797A3 (en) 1998-01-14
BR9510452A (pt) 1998-05-19
HK1008927A1 (en) 1999-07-16
DK1238677T3 (da) 2006-03-06
EP0814787B1 (en) 2002-10-30
CA2212794A1 (en) 1996-09-26
SE527123C2 (sv) 2005-12-27
AU710143B2 (en) 1999-09-16
MX9707005A (es) 1997-11-29
EP0814787A1 (en) 1998-01-07
ITMI950529A0 (it) 1995-03-17
EP1238677B1 (en) 2005-12-14
FI973702L (fi) 1997-09-16
DK0814787T3 (da) 2003-01-06
CH694396A5 (de) 2004-12-31

Similar Documents

Publication Publication Date Title
MX9707005A (es) Composiciones farmaceuticas que contienen 2,6-diisopropilfenol (propofol).
ES2097409T3 (es) Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
ES2139943T3 (es) Nuevos inhibidores de la sintasa de prostaglandina.
HUP9903544A2 (hu) Helyileg alkalmazható anesztetikus hatású gyógyszerkészítmény
BR0306874A (pt) Composições de 25-hidróxi vitamina d3
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2089497T3 (es) Derivados de 23-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que contienen estos derivados asi como su utilizacion como medicamentos.
ATE264851T1 (de) 4-fluoralkyl-2h-benzopyrane mit antiestrogener wirksamkeit
IS1664B (is) Ný aðferð við að framleiða útskipt 4-fenýl-4-píperídínkarboxamíð sem hefur bæði staðbundin deyfandiog kvalastillandi áhrif
PT916347E (pt) Solucoes farmaceuticas injectaveis contendo paracetamol e combinacoes de paracetamol com outras substancias activas
EP1121105A4 (en) PROPOFOL-BASED ANESTHETICS AND THEIR PRODUCTION METHOD
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
BR0112048A (pt) Processos para aumentar a distribuição de substâncias ativas para cuidados com a pele solúveis em óleos
DE69511418D1 (de) Lokalanästhetika und/oder Zentralanalgetika enthaltende pharmazeutische Zusammensetzungen
ES2143675T3 (es) Bencenosulfonil-ureas-tioureas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2109683T3 (es) Derivados de morfolina y tiomorfolina sustituidos en posicion 2 como antagonistas de gaba-b.
MX9307203A (es) COMPUESTOS ESTEROIDALES DE ACIL-3-CARBOXI-3,5-DIENO-17Ó Y 17ß -SUBSTITUIDOS.
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
YU20097A (sh) Fluorovani analozi vitamina d3, intermedijeri za njihovo dobijanje, postupak za dobijanje takvih fluorovanih analoga vitamina d3, farmaceutska smeša koja sadrži analoge fluorovanog vitamina d3 i upotreba takvih analoga u proizvodnji farmaceutske smeše za lečenje osteoporoze
BR9805926A (pt) Composição oleosa homogênea à base de borracha de silicone